ROCK1 and acute respiratory distress syndrome: Inhibitors of RHO-Kinase 1 (ROCK1) have been proposed to have beneficial effects against the severe acute respiratory distress syndrome (ARDS) associated with COVID-19 [30] as ROCK1 contributes to a burst in inflammation leading to ARS.